A Randomized Phase II Study Comparing Single-Agent Olaparib, Single-Agent Cediranib, and the Combinations of Cediranib/olaparib, Olaparib/durvalumab (MEDI4736), Cediranib/durvalumab (MEDI4736), and Olaparib/azd5363 (capivasertib) in Women with Recurrent, Persistent, or Metastatic Endometrial Cancer
JOURNAL OF CLINICAL ONCOLOGY（2023）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined